Chemotherapy versus transplants for acute myelogenous leukemia in second remission

R. P. Gale, M. M. Horowitz, J. K.H. Rees, R. G. Gray, M. M. Oken, E. H. Estey, K. M. Kim, M. J. Zhang, R. C. Ash, K. Atkinson, R. E. Champlin, K. A. Dicke, J. L. Gajewski, J. M. Goldman, W. Helbig, P. J. Henslee-Downey, W. Hinterberger, N. Jacobsen, A. Keating, J. P. KleinA. M. Marmont, H. G. Prentice, J. Reiffers, A. A. Rimm, P. A. Rowlings, K. A. Sobocinski, B. Speck, J. R. Wingard, M. M. Bortin

    Research output: Contribution to journalArticle

    63 Scopus citations

    Abstract

    The best therapy for persons with acute myelogenous leukemia (AML) in 2nd remission is unknown. Bone marrow transplants from an HLA-identical sibling are reported to be better than chemotherapy but this is controversial. The objective of the study was to compare 3-year leukemia-free survival (LFS) in comparable subjects receiving chemotherapy or a transplant. 485 persons with AML in 2nd remission were studied. The chemotherapy cohort included 244 persons treated on trials of the British Medical Research Council, Eastern Cooperative Oncology Group and MD Anderson Hospital. The transplant cohort included 257 persons transplanted worldwide and reported to the International Bone Marrow Transplant Registry (16 were also chemotherapy subjects). Subjects were selected for comparable age and year of treatment. Preliminary analyses identified two factors correlated with LFS: age ≤ or > 30 years and 1st remission duration ≤ or > 1 year; subsequent analyses were partitioned accordingly. Three-year probabilities of treatment-related mortality with chemotherapy and transplants were 7% (95% confidence interval, 3-15%) vs 56% (49-63%). Three-year leukemia relapse probabilities were 81% (74-86%) vs 41% (33-49%). Three-year probabilities of LFS were 17% (12-23%) vs 26 (20-32%). Cohort analysis showed significantly higher LFS with transplants vs chemotherapy in persons ≤ 30 years and 1st remissions > 1 year (41% (29-53%) vs 17% (7-32%); P = 0.017) and those in > 30 years with 1st remissions ≤ 1 year (18% (9-29%) vs 7% (2-16%); P = 0.046). Others had comparable LFS with both treatments. These data indicate better LFS with HLA-identical sibling transplants than chemotherapy in some persons with AML in 2nd remission.

    Original languageEnglish (US)
    Pages (from-to)13-19
    Number of pages7
    JournalLeukemia
    Volume10
    Issue number1
    StatePublished - Jan 1996

    Keywords

    • Acute myelogenous leukemia
    • Bone marrow transplant
    • Chemotherapy

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Chemotherapy versus transplants for acute myelogenous leukemia in second remission'. Together they form a unique fingerprint.

  • Cite this

    Gale, R. P., Horowitz, M. M., Rees, J. K. H., Gray, R. G., Oken, M. M., Estey, E. H., Kim, K. M., Zhang, M. J., Ash, R. C., Atkinson, K., Champlin, R. E., Dicke, K. A., Gajewski, J. L., Goldman, J. M., Helbig, W., Henslee-Downey, P. J., Hinterberger, W., Jacobsen, N., Keating, A., ... Bortin, M. M. (1996). Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia, 10(1), 13-19.